Reporting owner · CIK 0001818261

Catinazzo Thomas

Visual SEC Form 4 history across 1 companies, 7 transactions and 3 filings.

CFOChief Financial OfficerRelay Therapeutics, Inc.
Open-market mix
Latest filingAug 18, 2026, 08:16 PM
Filings3Form 4 records
Buying$00 purchases
Selling$618.1K5 sales
Net value−$618.1KBuys minus sells
Companies12 securities
Most recentAug 14, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-54Jan 251Aug 26

Net value flow

Buys minus sells

Jan 25
−$268.3K
Aug 26
−$349.7K

Transaction texture

Ownership and ticket size

Average P/S size$123.6K
Median P/S size$91.9K
Direct7
Indirect0
Aug 14, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern4Derivative Transactionfiling-context1Direct Ownershipfiling-context7Large Holdings Increaseholdings2Large Salesize2Repeat Sellerpattern310b5-1 Detectedfiling-context6

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Relay Therapeutics, Inc. on Aug 14, 2026 valued at $349,734.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Relay Therapeutics, Inc. on Aug 14, 2026 valued at $349,734.

Review SEC filing

Associated companies

Visual map of known reporting history

RLAYRelay Therapeutics, Inc.7 transactions · latest Aug 18, 2026, 08:16 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
RLAYCatinazzo Thomas
CFO
sale10b5-117.7k-$34.9MS
Direct Ownership Large Sale 10b5-1 Detected
−10.3%08/1808/14
RLAYCatinazzo Thomas
CFO
sale10b5-120.7k-$9.18MS
Cluster Selling Direct Ownership Large Sale+2
—01/31/202501/30/2025
RLAYCatinazzo Thomas
CFO
sale10b5-12.10k-$959kS
Cluster Selling Direct Ownership Repeat Seller+1
—01/31/202501/29/2025
RLAYCatinazzo Thomas
CFO
grant10b5-1139k$0A
Direct Ownership Large Holdings Increase 10b5-1 Detected
—01/31/202501/28/2025
RLAYCatinazzo Thomas
CFO
sale10b5-12.28k-$1.05MS
Cluster Selling Direct Ownership Repeat Seller+1
—01/31/202501/28/2025
RLAYCatinazzo Thomas
CFO
sale10b5-133.7k-$15.6MS
Cluster Selling Direct Ownership 10b5-1 Detected
—01/31/202501/28/2025
RLAYCatinazzo Thomas
CFO
grant275k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/15/202501/10/2025

Catinazzo Thomas Insider Activity FAQ

SEC Form 4 context

Who is Catinazzo Thomas?

Catinazzo Thomas is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001818261.

Which companies has Catinazzo Thomas reported transactions for?

Relay Therapeutics, Inc.

When was Catinazzo Thomas's latest insider buy?

No open-market insider purchase is available for this period.

When was Catinazzo Thomas's latest insider sale?

sale at Relay Therapeutics, Inc. on Aug 14, 2026 valued at $349,734.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.